What is KP Pharmaceutical Technology?
KP Pharmaceutical Technology operates as a premier Contract Development and Manufacturing Organization (CDMO), providing an end-to-end suite of services that span the entire drug development lifecycle. From initial preclinical formulation to complex commercial manufacturing, the firm leverages over a century of collective expertise to assist research organizations and pharmaceutical entities. Their state-of-the-art cGMP-compliant facilities serve as the backbone of their operations, ensuring that every stage of production meets rigorous regulatory standards. By offering specialized stability testing and clinical trial material manufacturing, the company acts as a critical partner for firms navigating the complex path toward regulatory approval and market entry.
How much funding has KP Pharmaceutical Technology raised?
KP Pharmaceutical Technology has raised a total of $232K across 1 funding round:
Debt
$232K
Debt (2021): $232K with participation from PPP
Key Investors in KP Pharmaceutical Technology
PPP
Public-Private Partnership
What's next for KP Pharmaceutical Technology?
With this late-stage financing secured, KP Pharmaceutical Technology is well-positioned to enhance its infrastructure and broaden its service portfolio. The strategic allocation of this capital will likely focus on increasing capacity within their cGMP facilities to meet the rising demand for outsourced drug development. As the pharmaceutical industry continues to prioritize efficiency and quality, the company is poised to capture additional market share by streamlining the transition from laboratory research to large-scale commercial production. Future growth will likely be driven by technological upgrades and the expansion of their technical team, further cementing their reputation as a reliable partner in the global life sciences supply chain.
See full KP Pharmaceutical Technology company page
